We previously described a nanovaccine platform targeting CD169+ cells using gangliosides, the endogenous ligands for CD169, and we showed that ganglioside-liposomes activated and delivered tumor antigens to Axl+ CD169+ DCs (20). This evidence concerns the gene SIGLEC1 and neoplasm.